BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:ONO-4578 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of ONO-4578\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06547385-2656@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:ONO-4578: Phase 1 readout est. (NCT06547385)
DESCRIPTION:ONO-4578\, phase 1.\nStudy: Study of ONO-4578 and XELOX/FOLFOX 
 Plus Bevacizumab in Colorectal Cancer\nEstimated primary completion: 31 Oc
 tober 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ono-4578#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0654
 7385
URL:https://assetmemo.bio/drug/ono-4578#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06948448-2656@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20280215
DTEND;VALUE=DATE:20280216
SUMMARY:ONO-4578: Phase 2 readout est. (NCT06948448)
DESCRIPTION:ONO-4578\, phase 2.\nStudy: A Study to Evaluate the Safety and 
 Efficacy of Two Dose Levels of ONO-4578 With Opdivo®\, in Combination Wit
 h mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With No
 n-MSI-H/dMMR\, PD-L1 Positive Advanced Colorectal Cancer\nEstimated primar
 y completion: 15 February 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/ono-4578#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06948448
URL:https://assetmemo.bio/drug/ono-4578#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03155061-2656@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:ONO-4578: Phase 1 readout est. (NCT03155061)
DESCRIPTION:ONO-4578\, phase 1.\nStudy: Study of ONO-4578 With and Without 
 ONO-4538 in Subjects Advanced or Metastatic Solid Tumors\nEstimated primar
 y completion: March 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/ono-4578#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT03155061
URL:https://assetmemo.bio/drug/ono-4578#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07818070-2656@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20310131
DTEND;VALUE=DATE:20310201
SUMMARY:ONO-4578: Phase 3 readout est. (NCT07818070)
DESCRIPTION:ONO-4578\, phase 3\, Gastric Cancer.\nStudy: A Trial of ONO-457
 8 Versus Placebo in Combination With Nivolumab and Chemotherapy in Partici
 pants With Gastric Cancer\, Esophagogastric Junction Cancer\, or Esophagea
 l Adenocarcinoma\nEstimated primary completion: January 2031. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/ono-4578#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07818070
URL:https://assetmemo.bio/drug/ono-4578#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
